Clinical Trial Research
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
Published in Drug Law Weekly, February 17th, 2009
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced that it will delay further partnership discussions regarding R788 until after results from the Phase 2b clinical trials of R788 are available. The company expects that these results, involving approximately 650 additional patients, will substantially further the understanding of R788's potential and may therefore drive enhanced economics in a possible deal. The company expects to have a collaboration partnership in place prior to initiating Phase 3 clinical trials. Enrollment in the two Phase 2b clinical trials of R788, TASKi2 and TASKi3, are ahead of schedule and the results from these clinical trials are expected to be available in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-02-17)
More Articles from Drug Law Weekly
- AARP
Consumer Advocates Call on Legislature to Support Governor's Ban on Pharmaceutical Gifts to Doctors - Addiction Medicine
'Prescription Drugs: Good Medicine - Bad Behavior;' Science Matters Program Explores the Rise in Prescription Drug Abuse Presented by the California Science Center - Alzheimer Disease
Anavex scales up synthesis of ANAVEX 2-73 for Phase 1 Alzheimer's disease study - Amarin
Amarin to Present at the 11th Annual BIO CEO & Investor Conference - Anti-Defamation League
ADL Praised the Commonwealth of Virginia State Attorney's Office - BDO Consulting Corporate Advisors, LLC
BDO Consulting Corporate Advisors Expands National Practice - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
